Hong Kong stock movement: LEE'S PHARM rises 15.42%

Hong Kong Stock Movement Stocks with High Trading Volume in the Industry Sihuan Pharmaceutical Holdings Group rose by 2.80%. Based on recent important news: On September 12, Sihuan Pharmaceutical announced that its self-developed SYH2066 tablets received approval from the National Medical Products Administration of China to conduct clinical trials in China. This drug is used to treat infections caused by respiratory syncytial virus and has good clinical development value, driving the stock price up. On September 12, the new drug application for KN026, developed in collaboration with Corning Jereh, was accepted by the National Medical Products Administration. This drug is used to treat HER2-positive gastric cancer, and clinical trials have shown significant efficacy, further boosting market confidence. On September 12, investment banks rated Sihuan Pharmaceutical with a buy recommendation, with a target average price of HKD 12.71, reflecting an optimistic market outlook on its future performance. The impact of policy changes in the pharmaceutical industry is significant. Fosun Pharma rose by 4.62%. According to recent important news: On September 14, Fosun Pharma adjusted its profit forecast; although the expected operating revenue was lowered, the net profit attributable to the parent company was raised, indicating enhanced profitability, which drove the stock price up. Data source: company report. Stocks with High Market Capitalization in the Industry Hengrui Medicine rose by 0.60%. Based on recent important news: On September 12, UBS Group increased its holdings in Hengrui Medicine by 204,400 shares, raising its stake to 7.04%. This move reflects market confidence in Hengrui Medicine, driving the stock price up. Data source: Zhitong Finance. On September 12, Hengrui Medicine's revenue from innovative drugs grew significantly, with sales and licensing revenue reaching CNY 9.561 billion, accounting for 60.66% of operating revenue. This growth trend has enhanced investor confidence in the company's future development. Data source: Zhitong Finance. On September 13, industry policy risks and macroeconomic volatility risks were mentioned, which may affect Hengrui Medicine's future development. However, the market remains optimistic about the continued growth of its innovative drugs. Data source: Zhitong Finance. The impact of policy changes in the industry is expected